Recent Updates — BMRN
BioMarin estimates its third-quarter 2026 GAAP and non-GAAP diluted earnings per share will decrease by approximately $1.50 due to a $283 million pre-tax acquired in-process research and development (IPR&D) expense related to the August acquisition of Alesta Therapeutics. The company anticipates total full-year 2026 pre-tax charges of roughly $320 million, representing an unfavorable impact of about $1.55 per share, as it prepares updated guidance for the remainder of the year. BioMarin is a biopharmaceutical company focused on discovering and developing innovative therapies for rare genetic diseases.
BioMarin Pharmaceutical Inc. entered into a Settlement and License Agreement with Ascendis Pharma A/S on September 24, 2026, superseding a prior term sheet effective August 28, 2026. BioMarin granted Ascendis a non-exclusive, worldwide license to develop and commercialize TransCon CNP (navepegritide) for indications including achondroplasia and hypochondroplasia. In exchange, Ascendis will pay royalties of 20% on U.S. net sales and 18% on net sales in the European Union, Brazil, and South Korea until May 2030. The agreement includes the dismissal with prejudice of pending patent litigation between the parties. BioMarin Pharmaceutical Inc. operates in the biotechnology industry, focusing on the discovery and development of treatments for rare genetic diseases.
On September 15, 2026, BioMarin Pharmaceutical Inc. announced the discontinuation of development for VOXZOGO in children with Noonan syndrome. The decision followed an assessment of study feasibility and the current treatment landscape, rather than safety or efficacy concerns regarding the drug. This strategic withdrawal impacts a specific pediatric indication but does not alter the company's broader pipeline or commercial operations. BioMarin Pharmaceutical Inc. operates in the biotechnology industry, focusing on the discovery, development, and commercialization of therapies for rare genetic diseases.
On September 10, 2026, BioMarin Pharmaceutical Inc.'s Board of Directors increased its size from ten to eleven members and appointed Robert Plenge, M.D., Ph.D., as an independent non-employee director. Dr. Plenge was simultaneously appointed to the Science and Technology Committee. In connection with his appointment, he received restricted stock units valued at $400,000 under the Company’s 2017 Equity Incentive Plan, vesting prior to the next annual meeting. He will receive standard director fees and committee retainers as outlined in the company's proxy statement. BioMarin Pharmaceutical Inc. operates in the biotechnology industry, focusing on the discovery, development, and commercialization of therapies for rare genetic diseases.
BioMarin Pharmaceutical Inc. completed its acquisition of Alesta Therapeutics B.V. on August 31, 2026, making Alesta a wholly owned subsidiary. The transaction was executed pursuant to a Share Purchase Agreement previously announced on August 18, 2026. BioMarin operates in the biotechnology industry, focusing on the development and commercialization of therapies for rare diseases.
BioMarin entered into a binding term sheet with Ascendis Pharma to resolve all pending global patent litigation regarding the TransCon CNP asset, navepegritide (Yuviwel). Under the agreement, BioMarin grants Ascendis a non-exclusive, worldwide license for Yuviwel across all indications. In exchange, Ascendis will pay royalties of 20% on U.S. net sales and 18% on net sales in the EU, Brazil, and South Korea until May 2030. The settlement includes retroactive royalty application from first commercial sale and dismissal of all related legal proceedings. BioMarin is a biotechnology company focused on developing treatments for rare genetic diseases.